On September 24, 2024 Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to I ), reported that it has entered into a strategic collaboration with Alkyon Therapeutics, Inc. (AlkyonTx), a San Diego-based biotechnology company, to develop next-generation immunotherapy and other targeted therapy applications, using Nona’s Harbour Mice fully human antibody platform (Press release, Nona Biosciences, SEP 24, 2024, View Source [SID1234646848]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Nona Biosciences’ proprietary Harbour Mice platform has extensive potential for generating both conventional and novel heavy chain only (HCAb) antibodies that are fully human, affinity matured with excellent solubility and developability, enhancing the efficacy and precision of advanced therapies. The technology is clinically validated, globally patent protected, and worldwide endorsed and recognized.
"We are excited to partner with Alkyon Therapeutics and support their efforts to harness the power of big data in drug discovery," said Dr. Jingsong Wang, Chairman of Nona Biosciences. "This agreement underscores our dedication to leveraging our world-leading antibody discovery technologies in diverse applications to accelerate oncology drug development and enhance translatability to the clinic."
"At Alkyon, we are eager to work with Nona Biosciences, utilizing their Harbour Mice platform to advance our immunotherapy research," said Dr. Benjamin Titz, Co-Founder of Alkyon Therapeutics, Inc. "By leveraging its proprietary platform to generate deep insights into the tumor microenvironment—particularly the extracellular matrix (ECM) and stroma—Alkyon uncovers novel therapeutic targets with enhanced translational potential, accelerating the development of breakthrough treatments for solid cancers."